Parecoxib suppresses the increase of neutrophil-to-lymphocyte ratio after the modified radical mastectomy
10.11817/j.issn.1672-7347.2017.09.009
- VernacularTitle:帕瑞昔布抑制乳腺癌改良根治术后中性粒细胞与淋巴细胞比值升高
- Author:
Yunli LI
1
;
Lei ZHOU
;
Xiaoxiao LI
;
Gong CHEN
;
Kaiming DUAN
;
Boni DING
;
Wen OUYANG
Author Information
1. 中南大学湘雅三医院麻醉科
- Keywords:
breast cancer;
perioperative period;
parecoxib;
neutrophil-to-lymphocyte ratio
- From:
Journal of Central South University(Medical Sciences)
2017;42(9):1048-1052
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effect of parecoxib on neutrophil-to-lymphocyte ratio (NLR)after the modified radical mastectomy,and to explore its potential mechanisms for inhibition ofperioperative inflammation.Methods:A total of 40 breast cancer patients undergone the modified radical mastectomy were randomly divided into a parecoxib group (n=20) and a control group (n=20).The parecoxib group received intravenous parecoxib (40 mg,5 mL) during general anesthesia induction,post-operative day 1 and day 2;the control group received intravenous normal saline (5 mL) at the corresponding time points.Their peripheral bloods were collected for routine test in the morning of the surgery day (T1),and Day 1 (T2),Day 3 (T3) and Day7 (T4) after the surgery, and NLRwas calculated.Results:Compared with T1,NLR in the control group at T2 and T3 was significantly increased (P＜0.05),but not at T4 (P＞0.05);NLR in the parecoxib group was sharply increased at T2 (P＜0.01),and returned to preoperative levels at T3 and T4 (P＞0.05).NLR in the parecoxib group was significantly lower than that in the control group at T2 (P＜0.05),but there were no significant difference between the two groups at other time points (P＞0.05).Conclusion:Parecoxib can restrain the inflammatory responses and improve immune function of the breast cancer patients by suppressing the elevation of NLR after the modified radical mastectomy,which is expected to improve the prognosis of the breast cancer patients.
